Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Yi‐Long Wu, Tony Mok, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu,

Annals of Oncology

Egfr T790mOverall SurvivalMedicinePathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerCancer Growth